Market Closed -
Nasdaq
15:59:44 2024-06-04 EDT
|
5-day change
|
1st Jan Change
|
17.1
USD
|
+0.29%
|
|
+14.00%
|
+27.42%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
357.6
|
563.4
|
-
|
-
|
Enterprise Value (EV)
1 |
236.1
|
338.5
|
443
|
563.4
|
P/E ratio
|
-1.08
x
|
-6.83
x
|
-6.99
x
|
-7.89
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
501
x
|
188
x
|
EV / Revenue
|
-
|
-
|
394
x
|
188
x
|
EV / EBITDA
|
-3,459,997
x
|
-
|
-
|
-
|
EV / FCF
|
-3.96
x
|
-4.34
x
|
-5.06
x
|
-6.22
x
|
FCF Yield
|
-25.2%
|
-23%
|
-19.8%
|
-16.1%
|
Price to Book
|
3.15
x
|
3.84
x
|
3.14
x
|
5.4
x
|
Nbr of stocks (in thousands)
|
26,646
|
32,945
|
-
|
-
|
Reference price
2 |
13.42
|
17.10
|
17.10
|
17.10
|
Announcement Date
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
1.125
|
3
|
EBITDA
|
-
|
-68.24
|
-
|
-
|
-
|
EBIT
1 |
-
|
-68.51
|
-92.54
|
-104.7
|
-136.4
|
Operating Margin
|
-
|
-
|
-
|
-9,310.64%
|
-4,546.47%
|
Earnings before Tax (EBT)
1 |
-
|
-66.39
|
-76.49
|
-91.53
|
-79.66
|
Net income
1 |
-59.28
|
-66.39
|
-74.59
|
-86.04
|
-79.27
|
Net margin
|
-
|
-
|
-
|
-7,647.69%
|
-2,642.22%
|
EPS
2 |
-36.34
|
-12.40
|
-2.503
|
-2.446
|
-2.167
|
Free Cash Flow
1 |
-
|
-59.61
|
-77.93
|
-87.5
|
-90.6
|
FCF margin
|
-
|
-
|
-
|
-7,777.78%
|
-3,020%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/29/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-20.12
|
-
|
-23.22
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.27
|
-14.97
|
-23.29
|
-26
|
-28
|
-30
|
-33
|
-36
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-20.11
|
-14.19
|
-21.68
|
-22
|
-24
|
-26
|
-
|
-
|
Net income
1 |
-20.11
|
-14.19
|
-21.68
|
-18.18
|
-18.18
|
-14.67
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.220
|
-
|
-0.7700
|
-0.5991
|
-0.5657
|
-0.5124
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/23
|
3/11/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
121
|
225
|
120
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-59.6
|
-77.9
|
-87.5
|
-90.6
|
ROE (net income / shareholders' equity)
|
-
|
-58.5%
|
-61.9%
|
-46.2%
|
-47.2%
|
ROA (Net income/ Total Assets)
|
-
|
-56.1%
|
-51%
|
-39.9%
|
-40.8%
|
Assets
1 |
-
|
118.4
|
146.1
|
215.5
|
194.5
|
Book Value Per Share
2 |
-
|
4.260
|
4.450
|
5.450
|
3.170
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.12
|
2.43
|
2.73
|
3.15
|
Capex / Sales
|
-
|
-
|
-
|
242.96%
|
105%
|
Announcement Date
|
9/29/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
17.1
USD Average target price
21.4
USD Spread / Average Target +25.15% Consensus |
1st Jan change
|
Capi.
|
---|
| +27.42% | 562M | | +46.19% | 56.65B | | -6.14% | 39.44B | | +39.19% | 39.03B | | -6.65% | 26.86B | | +12.33% | 26.75B | | -21.78% | 19.03B | | -0.35% | 12.28B | | +24.18% | 12.26B | | +28.38% | 12.04B |
Other Biotechnology & Medical Research
|